Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCapital LeasesCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - AccuredRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

SAB Biotherapeutics (SABSW) Shares Outstanding (2020 - 2025)

SAB Biotherapeutics' Shares Outstanding history spans 6 years, with the latest figure at $47.7 million for Q4 2025.

  • For Q4 2025, Shares Outstanding rose 410.13% year-over-year to $47.7 million; the TTM value through Dec 2025 reached $47.7 million, up 410.13%, while the annual FY2025 figure was $47.7 million, 410.13% up from the prior year.
  • Shares Outstanding reached $47.7 million in Q4 2025 per SABSW's latest filing, roughly flat from $47.5 million in the prior quarter.
  • In the past five years, Shares Outstanding ranged from a high of $47.7 million in Q4 2025 to a low of -$546658.0 in Q1 2022.
  • Average Shares Outstanding over 5 years is $16.6 million, with a median of $9.3 million recorded in 2024.
  • Peak YoY movement for Shares Outstanding: plummeted 102.1% in 2022, then skyrocketed 112349.08% in 2025.
  • A 5-year view of Shares Outstanding shows it stood at $26.0 million in 2021, then plummeted by 80.39% to $5.1 million in 2022, then soared by 82.18% to $9.3 million in 2023, then grew by 0.68% to $9.3 million in 2024, then surged by 410.13% to $47.7 million in 2025.
  • Per Business Quant, the three most recent readings for SABSW's Shares Outstanding are $47.7 million (Q4 2025), $47.5 million (Q3 2025), and $9.3 million (Q2 2025).